AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05531474 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical Weight Management
Description: The current standard medical practice for weight loss that is available at the local participating centre, reflecting the local standard of care
Study NCT02669030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suvorexant
Description: an FDA-approved sleep aid
Study NCT02669030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: control group
Study NCT03251339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB11455
Description: Participants received a single subcutaneous injection of MSB11455 6 milligram (mg) per (/) 0.6 milliliter (mL) on Day 1 in morning of treatment period 1 (28 Days) and 2 (28 Days). Period 1 and Period 2 are separated by a washout period of 35 Days.
Study NCT03251339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: US-Neulasta
Description: Participants received a single subcutaneous injection of US-Neulasta 6 mg/0.6 mL on Day 1 in morning of treatment period 1 and 2. Period 1 and Period 2 are separated by a washout period of 35 Days.
Study NCT02068235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponesimod 5mg i.v.
Study NCT02068235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponesimod i.v.
Description: Dose and infusion rate will be adjusted according to the results of the pilot phase
Study NCT02068235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponesimod 10 mg tablet
Study NCT02425163 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transrectal shear wave elastography of the prostate
Description: Transrectal shear wave elastography of the prostate with SuperSonic Imagine Ultrasound System AIXPLORER and an endocavity sonic head SE12-3 (SuperSonic Imagine, Aix-en-Provence, France)
Study NCT02425163 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transrectal random biopsy of the prostate
Description: TRUS-SWE-guided random biopsies of the Prostata with 18G-gun
Study NCT01398514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram 10mg/day or matched pill placebo
Study NCT01398514 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram 10mg/day or matched pill placebo
Study NCT02268968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% Gel
Description: Lidocaine 2% gel will be applied to nostrils and nasal CPAP prong 5 minutes prior to application of nasal CPAP
Study NCT03536533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergame
Description: Each of the 8 exercise sessions will last at least 42 minutes, with an actual training duration of 21 minutes. The participants will be accustomed gradually to the game. On one hand this will be achieved by increasing the difficulty in subsequent levels within the exergame.
Study NCT02012348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibacterial soap with triclocarban
Study NCT02012348 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antibacterial soap + benzalkonium chloride
Study NCT02012348 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control soap
Study NCT02213289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab
Study NCT02213289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-806
Description: ABT-806
Study NCT02213289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemarituzumab
Description: Bemarituzumab
Study NCT02213289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab
Study NCT02213289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab
Study NCT02213289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard cytotherapy
Description: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)
Study NCT02213289 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard cytotherapy
Description: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)
Study NCT02106897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059 (litifilimab)
Description: See Arm Descriptions
Study NCT02106897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See Arm Descriptions
Study NCT02013791 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sham
Description: Sham administered to non-study eye as per protocol on Day 1
Study NCT02013791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine New Ophthalmic Formulation
Description: Cyclosporine New Ophthalmic Formulation administered as per protocol
Study NCT04601480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice Architecture Nudge
Description: During the choice architecture nudge intervention, Primary Care Providers (PCPs) will be sent alerts in the Electronic Health Record (EHR) system when they initiate an opioid order for a patient will a current opioid prescription. The alerts prompt PCPs to consider tapering the patient's opioid. The alert also displays the MME of the patient's current opioid prescription and automatically calculates what a 10% reduction in MME relative to the current prescription would be. The alert contains options to either cancel the refill order, or to continue with the order.
Study NCT04601480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PMP Integration & Nudge
Description: During the Prescription Drug Monitoring Program (PMP) integration \& nudge intervention, Primary Care Providers (PCPs) will have integrated access to the PMP embedded within the EHR. All clinicians can already access the PMP to look up a patient's prior opioid prescriptions and prescription fills. However, this process involves signing in to the separate PMP website and can be complicated and time-consuming within typical clinical workflow. The integrated PMP tool makes it much easier and faster for a PCP to access the PMP information for a given patient.
Study NCT00828737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadovist, BAY86-4875)
Description: Gadovist in approved indications at approved dosages
Study NCT00945100 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye Patch
Description: 42 hours patching per week (averaging 6 hours patching daily)
Study NCT03833479 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Further Treatment
Description: No further treatment
Study NCT03833479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSR-042
Description: Fixed 500 mg TSR-042 dose Q3W for the first 4 doses followed by a fixed 1000 mg TSR-042 dose Q6W for up to 24 months
Study NCT00118846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 25 gm soy protein supplement
Description: 25 gm soy protein supplementation administered in equally divided dosage twice daily (12.5 gm)
Study NCT00118846 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Milk protein administered twice daily
Study NCT00945100 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye Patch
Description: 2 hours patching daily
Study NCT03013855 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FIT-SOC
Description: Study subjects will be given a standard kit for fecal immunochemical test by their primary healthcare provider. As per standard practice, the patient will take the kit home and use the included FIT applicator to collect a stool sample from spontaneously passed stool during a regular bowel movement. The patient will then mail the stool sample to the lab in a pre-paid envelope, which is provided in the kit.
Study NCT01931488 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MIBG label with I123 or I124
Description: PD Patients who are not allergic to Iodine will be given 8 drops of Lugol . 30 min later, patients will be injected with 123I-MIBG 6 mci (222 MBq). 3 hours post-injection patients will undergo planar and SPECT imaging. at another day, patients will be injected with 124I-MIBG 0.8 mci (29.6 MBq). 3 hours post-injection patients will undergo PET-CT imaging.whole-body imaging. in the evaluation of neuroendocrine tumors-Patients who are not allergic to Iodine will be given 8 drops of Lugol.30 min later, patients will be injected with 123I-MIBG 6 mCi (222 MBq).3 hours and 24 hours post-injection patients will undergo planar and SPECT imaging. at another day, patients will be injected with 124I-MIBG 0.8 mCi (29.6 MBq). 3 hours and 24 hours post-injection patients will undergo PET-CT imaging.
Study NCT01931488 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SPECT imaging
Study NCT03013855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FIT-DRE
Description: Study subjects will have a digital rectal exam completed by their primary care providers during the physical exam portion of a routine clinic visit. The stool collected on the examiner's finger will be applied to the FIT applicator in the standard kit, which will then be sent to the lab for processing.
Study NCT00802932 — intervention group
Intervention type: DEVICE
Intervention: Non-contrast Computed Tomography (CT) Scans (Metallic Markers)
Description: Non-contrast CT Scans prior to start of radiation therapy, and during weeks 2, 4, 6.
Study NCT00802932 — intervention group
Intervention type: DEVICE
Intervention: Non-contrast CT Scans (Metallic Markers)
Description: Non-contrast CT Scans prior to start of radiation therapy and on Day 5.
Study NCT04338139 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone regeneration
Description: bone regeneration using bio-oss collagen
Study NCT02241213 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS-r)
Description: 10 sessions, each session of EMT-r will be low frequency (1 Hz for 20 minutes and a total of 1200 pulses) using a biphasic pulse stimulator, with active coil (coil-shaped focal or inactive coil placebo for 2 weeks from Monday to Friday, target: triangular portion - homologous to injury Inferior front Gyrus (GFI).
Study NCT02241213 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Transcranial Magnetic Stimulation
Description: 10 sesions of Non- active coil, that will simulate the sound of the TMS, holding the coil on the scalp at an angle of 45 degrees in the selected area
Study NCT02274831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Email Reminder of need to follow up with primary physician
Study NCT02600689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise training
Study NCT02600689 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive exercise training
Study NCT01092559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide generated by the GeNO nitrosyl delivery system
Description: single short-term exposure to inhaled nitric oxide using the GeNO nitrosyl delivery system.
Study NCT02630498 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brachial plexus block
Description: Patients receiving brachial plexus block for hand/arm surgery
Study NCT02643082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFF MDI (PT003) 14.4/9.6μg
Description: Glycopyrronium and Formoterol Fumarate
Study NCT02643082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Description: Comparator: Placebo MDI which contains no active ingredients
Study NCT02239757 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left radial approach
Description: Primary PCI performed through left radial approach.
Study NCT02239757 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right radial approach
Description: Primary PCI performed through right radial approach.
Study NCT01324999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: 20mg/day for one month then 40mg/day for additional 4 months
Study NCT00632242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC1779
Description: Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min.
Study NCT00632242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC1779
Description: Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min.
Study NCT00632242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC1779
Description: Initial stepwise infusion of 0.46 mg/kg over 30 minutes and subsequent continuous infusion of an additional 2.88 mg/kg given over 24 hours at a rate of 0.002 mg/kg/min.
Study NCT00632242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC1779
Description: Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min to produce a target plasma concentration of 6 mcg/mL.~Continuous infusion of ARC1779 Injection may continue for ≤ 14 days. After initial 24 hours dose may be titrated to achieve a target plasma concentration of 12 mcg/mL as needed, on the basis of clinical and laboratory data, according to the Investigator's judgment.
Study NCT01830790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: Single dose of 100mg Sildenafil citrate
Study NCT01830790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil citrate
Description: Single dose of 100mg Sildenafil citrate
Study NCT03551288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUVN-911
Description: Tablet
Study NCT01244594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling with functional electrical stimulation
Description: Subjects will cycle with functional electrical stimulation for one hour, 3 times per week at Magee Rehab's outpatient center. Subjects will cycle for a total of 26 weeks (6 months).
Study NCT00957944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rotigotine transdermal patch (Neupro®)
Description: Rotigotine 4.5 mg/10 cm\^2 patch applied for 24 hours
Study NCT03628482 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CRF
Description: For continuous radiofrequency ablation the electrode tip temperature was raised to 80°C during 90 s.
Study NCT03628482 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF
Description: The procedure for PRF is almost identical to that applied for CRF, except that the current is typically carried out in 20 ms pulses every 0.5 s at a temperature that does not exceed 42 °C during 360 s.
Study NCT03581695 — intervention group
Intervention type: OTHER
Intervention: Blood test
Description: Blood test
Study NCT03759886 — intervention group
Intervention type: DRUG
Intervention: Paromomycin Sulfate Powder
Description: The patients receive Paromomycin and Metronidazole the day prior to colorectal surgery after mechanical bowel preparation
Study NCT01034566 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Study NCT02867813 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: subjects will receive evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.
Study NCT06658379 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CD8+TEMRA
Study NCT00223405 — intervention group
Intervention type: DEVICE
Intervention: crown placement
Study NCT00632242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC1779
Description: In one period of the sequence, ARC1779 will be administered to all subjects as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min in combination with a dummy 30-minute infusion of placebo. In another period, subjects will receive a single infusion of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes in combination with a dummy 30-minute stepwise infusion followed by 4-hour continuous infusion of placebo. In the one other period, subjects will receive the combination of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes and ARC1779 given as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min
Study NCT04304807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 20 mg
Description: Melatonin was given as a total dose of 20 mg via enteral route in two doses of 10 mg each with a 1 hour interval in between.
Study NCT04304807 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Traditional antibiotic treatment
Description: Traditional antibiotic treatment was given to both groups with feeding intolerance according to treatment protocols by neonatal intensive care units of Ain Shams University
Study NCT04541862 — intervention group
Intervention type: OTHER
Intervention: Intensive care
Description: intensive care for critically ill patients in the intensive care units
Study NCT04357678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qi Gong Programme
Description: Warm-up: In warm up session joint activities were performed along with light stretching. Patients performed these activities with instructor's commands for 5 minutes.~Liu Zi Jue exercise: patients performed intact Liu Zi Jue exercise (form of Qigong).~This includes six healing sounds, Xu, He, Hu, Si, Chui, Xi and the Harmonized actions along with the instructor for 20 minutes. Cooling-down: After completion of Qigong, patient done gentle stretching to adjust back their breathing and this cool down session lasted for 5 minutes. Subjects received supervised training session for 30 min twice a week.
Study NCT04357678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short Form Sun Style Tai Chi
Description: Commencing Movement, Opening and closing hand, Single whip, Waving hands in the cloud, Opening and closing hands, Brush knee, Playing lute, Perry and Punch, Block and close, Pushing the mountain, Closing movement.~Participants attended two supervised 30min sessions twice a week. Participants learnt 3 to 4 forms per week and at the completion of study (which is the six week of training), they completed all 21 forms. In each training session, participants revised previous SSTC forms that they learnt earlier up to that session.
Study NCT00634530 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dietary Advice
Description: The specific dietary advices according to nutritional status. Main advices: reduction of fat and sugar intake, increase of total energy, dairy intake of vegetables and fruits.
Study NCT03714867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg
Description: 150 mg concealed pregabalin capsule
Study NCT03714867 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Concealed placebo capsule
Study NCT03973385 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Cryotherapy
Description: patients recieving cryotherapy for skin anesthesia for artérial blood gas
Study NCT03973385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: patients recieving cryotherapy for skin anesthesia for artérial blood gas
Study NCT04355845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Description: 25 milligrams (mg) single dose tablet
Study NCT04355845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: PF-06651600 400 mg single dose
Study NCT03737643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab by intravenous infusion. In tBRCAm cohort bevacizumab is optional according to local practice.
Study NCT03737643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab by intravenous infusion. In tBRCAm cohort bevacizumab is optional according to local practice.
Study NCT03737643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab by intravenous infusion
Study NCT01129960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (BIA 2-093)
Description: Tablets will be used.
Study NCT01129960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets will be used.
Study NCT03737643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib tablets
Study NCT03737643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo olaparib
Description: Placebo tablets to match olaparib
Study NCT03737643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo olaparib
Description: Placebo tablets to match olaparib
Study NCT00892762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost APS 40 micrograms/ml eye drop solution
Description: non-BAK (benzalkonium chloride) medication
Study NCT03737643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab placebo
Description: Matching placebo for intravenous infusion
Study NCT03737643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin+Paclitaxel
Description: Standard of care chemotherapy
Study NCT03737643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin+Paclitaxel
Description: Standard of care chemotherapy
Study NCT03324646 — intervention group
Intervention type: DRUG
Intervention: [11C]PS13
Description: A novel PET ligand to selectively image COX-1